BioVie Inc. (BIVI) Stock

BioVie Inc. (BIVI) is a Healthcare stock trading at $1.95 (as of 2026-08-21), with a market capitalization of $14.71M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BioVie Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing drug therapies in the United States. Its pipeline includes BIV201 for ascites due to chronic liver cirrhosis (completed Phase IIa), and NE3107 for mild to moderate Alzheimer’s disease (Phase III) and Parkinson’s disease (Phase I), with additional preclinical work in multiple myeloma and prostate cancer.

Valuation — source: SEC EDGAR (first-party)
Price$1.95
Market Cap$14.71M
Price / Book1.43
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDiametric Capital, LP ($518000.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCuong Viet Do
Employees14
CountryUS
IPO Date2020-09-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adial Pharmaceuticals, Inc. (ADIL)
  • Bullfrog AI Holdings, Inc. Common Stock (BFRG)
  • Theriva Biologics, Inc. (TOVX)
  • MetaVia Inc. (MTVA)
  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
  • Soligenix, Inc. (SNGX)
  • Azitra, Inc. (AZTR)
BIVI earnings history · BIVI institutional & insider holders · BIVI KPIs & operating metrics · BIVI financials · BIVI investor presentations & press releases · BIVI SEC filings · BIVI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.